Pharmaceutical Market Europe • July/August 2022 • 46-48
APPOINTMENTS
Hanover Health
Ian Dodge
Hanover Health has appointed Ian Dodge as a senior adviser. Dodge brings extensive experience, having served as the former NHS England national director of strategy, primary care and community services. From 2014 to 2022, Dodge served as part of the NHS England Board and Executive leadership team, and during his time with the organisation, he led NHS England’s approach to the current NHS reforms and reorganisation. Additionally, he spearheaded the organisation’s innovation and transformation work amongst other responsibilities. Before joining NHS England, he was director of the NHS Group and head of policy for the Department of Health, while in 2005-2006, Dodge served as the Prime Minister’s senior adviser on the NHS.
Teva Pharmaceutical Industries
Eric Hughes
Teva Pharmaceutical Industries has appointed Eric Hughes as executive vice president of global R&D and chief medical officer. Hughes brings 20 years’ leadership experience to the role, having recently served at Vertex Pharmaceuticals as senior vice president of clinical development and translational medicine. He worked as head of the immunology, hepatology and dermatology global development unit at Novartis.
CureVac
Myriam Mendila
CureVac has appointed Myriam Mendila as its chief development officer. Mendila brings over 20 years of experience in global product development, medical affairs, pharmacovigilance and healthcare compliance alongside global product strategy, including commercial strategy at Roche, Genentech and Novartis. Mendila served as worldwide head of medical affairs and chief medical officer oncology at Novartis Pharma, Switzerland.
Insilico
Feng Ren
Insilico has appointed Feng Ren as its chief scientific officer. Ren joins the company from Medicilon where he served as a senior vice president. Ren spent 11 years in discovery and development of small molecule drugs at GlaxoSmithKline (now GSK). Here, he also worked as the company’s chief researcher, programme leader, director and head of chemistry of Neurodegeneration DPU.
Element Materials Technology
Michael Kipping
Element Materials Technology has appointed Michael Kipping as director of medical technologies for Europe. Previously, Kipping served as health innovation lead at Innovate UK (UKRI) and ran the primary grant funding programme supporting innovative UK health and life sciences businesses. He also worked with stakeholders to develop a proposal for a UK Centre of Excellence for Regulatory Science & Innovation.
Adrenomed
Steffen Stürzebecher
Adrenomed has appointed Steffen Stürzebecher as chief medical officer. Stürzebecher brings extensive clinical development experience to the role, having worked in phase 3 trials and regulatory submissions. He served at Grünenthal as chief medical officer, head of R&D portfolio management, head of global development and as head of global medical sciences, and was recently chief medical officer of Eisbach Bio GmbH.
ADC Therapeutics
David Gilman
ADC Therapeutics has appointed David Gilman as chief business and strategy officer. Gilman will oversee all business development and portfolio strategy efforts worldwide. With over 25 years’ experience as a pharmaceutical business executive, he joins the company from ClearView Healthcare Partners. Gilman previously served as the global head of portfolio strategy and business for Novartis Oncology.
ADC Therapeutics
Jean-Pierre Bizzari
ADC Therapeutics has appointed Jean-Pierre Bizzari to its board of directors. Bizzari has over 35 years’ experience in oncology drug development, having served as executive vice president and group head of clinical oncology development at Celgene Corporation. He currently serves on the advisory boards of France’s National Cancer Institute and the European Organisation for Research and Treatment of Cancer.
Element Materials Technology
Nicole Small
Element Materials Technology has appointed Nicole Small as senior manager of the medical technology team. Small served as a senior manager at the Medicines and Healthcare products Regulatory Agency in the devices safety and surveillance group. She has influenced major change in educational and operational programmes, having led the agency’s COVID-19 response to secure medical devices and PPE for the UK.
Pistoia Alliance
Becky Upton
The Pistoia Alliance has appointed Becky Upton as its first woman president. In her new role, which began on 1 July 2022, Upton will be responsible for leading the Alliance’s strategy, while moulding its future in managing data standards, diversity and inclusion, sustainability and precision medicine. Upton first became involved with the Pistoia Alliance with its Lab of the Future project, while she served at VWR – now part Avantor – for over ten years in sales, business development and scientific services. After VWR, she joined Pion as its managing director. Upton then went on to become chief portfolio officer and also served as a director at Impellam Group.
Valneva
Thomas Decker
Valneva has appointed Thomas Decker to its Scientific Advisory Board. Decker is a professor of immunobiology at the Max Perutz Labs at the University of Vienna, bringing 30 years’ research and teaching experience to the role. He served as a consultant for a variety of pharmaceutical companies and is the current president of the European Macrophage and Dendritic Cell Society (EMDS).
Valneva
Michael Pfleiderer
Valneva has appointed Michael Pfleiderer to its scientific advisory board. Pfleiderer is an expert in the development of vaccines, holding a PhD in molecular virology. Pfleiderer served as the head of the human viral vaccines section at the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines, contributing to European Medicines Agency and World Health Organization guidelines on regulatory issues.
Achilles Therapeutics
James Taylor
Achilles Therapeutics has appointed James Taylor as its chief business officer. With a career spanning over 25 years in the pharmaceutical and biotechnology industries, Taylor has served as chief business officer at Sosei Heptares and spearheaded deals with Genentech, Takeda, AbbVie, GSK, Verily, Aditum and Biohaven Pharmaceuticals. He also served as a senior director at GSK.
Element Materials Technology
Elisabeth Lackner
Element Materials Technology has appointed Elisabeth Lackner as its chief scientific officer. Lackner brings a wealth of executive pharmaceutical and biotechnology experience. She joins from Vineta, where she served as managing director. She served at ABF Pharmaceutical Services and GBA Group Pharma, working as the CEO of the GBA Pharma Division. Lackner also serves as a consultant in life sciences.
Amolyt Pharma
Mark Sumeray
Amolyt Pharma has appointed Mark Sumeray as its chief medical officer. Sumeray brings over 20 years’ experience to the role, joining the company from Amryt Pharmaceuticals where he served as chief medical officer. He led clinical and scientific interactions with the US Food and Drug Administration and the European Medicines Agency. Sumeray previously served as chief medical officer at Aegerion Pharmaceuticals.
British Generics Manufacturers Association
Peter Kelly
The British Generics Manufacturers Association has appointed Peter Kelly as its chair. Kelly was previously vice-chair and takes the promotion with over 20 years’ experience in the pharmaceutical industry. In the last 15 years, he has been at Accord in various senior commercial roles. He previously chaired the British Generics Manufacturers Association Economic and Commercial working group.
atai Life Sciences
Stephen Bardin
atai Life Sciences has appointed Stephen Bardin as its chief financial officer. Bardin currently serves at BridgeBio Pharma as senior vice president of finance and operations and began serving atai Life Sciences as chief financial officer designate from 27 June. Bardin has previously served in finance, operations and corporate development at Myovant Sciences, Halo Neuroscience.
Charnwood Molecular
Laie Abello
Charnwood Molecular has appointed Laie Abello as its director of drug metabolism and pharmacokinetics. Abello joins the company from BenevolentAI where she served as a principal scientist. In 2010, she began her career at Almirall as a junior scientist and then moved onto Almac Discovery. Following this, Abello served Xenogesis where she served as a team leader and senior scientist.
Evoke KYNE
Maureen Byrne
Evoke KYNE has appointed Maureen Byrne as president. Byrne will oversee global leadership, including management of its client portfolio and executive leadership team. Byrne has nearly 30 years’ experience as a health communicator and served at Novartis as a senior director of global oncology public relations, as head of global sales and strategy communications and as director of public relations.
Evoke KYNE
Stephanie DeViteri
Evoke KYNE has appointed Stephanie DeViteri as its head of North America. DeViteri brings 20 years’ experience having worked across health areas including Crohn’s disease and ulcerative colitis and reproductive health. She has helped to shape disease awareness campaigns and patient advocacy engagement. She has been named as a “Rising Star” by the Healthcare Businesswomen’s Association and is a PharmaVOICE 100 honoree.
Evoke KYNE
Kaitlyn Belicose
Evoke KYNE has appointed Kaitlyn Belicose as its new executive vice president, managing director, New York. Belicose has been at the agency for over five years and in her new role will oversee daily operations, growth and team management of the NY office. She previously served at Edelman as vice president, working across the pharmaceutical, social purpose and consumer health divisions.
Evoke KYNE
Celeste Farzetta
Evoke KYNE has appointed Celeste Farzetta as its new executive vice president, managing director, Philadelphia. Farzetta has served 15 years at the agency and will now lead daily operations, growth and team management of the Philadelphia office. She previously served as vice president at Tonic Life Communications and she also served as an assistant account executive at Dorland Global.
Evoke KYNE
Darcy Sawatzki
Evoke KYNE has appointed Darcy Sawatzki as its executive vice president head of public health and team lead, Los Angeles. Sawatzki previously spent 18 years at Hager Sharp where she served as the project manager for communications contracts with the US Department of Health and Human Services’ Office on Women’s Health (HHS OWH), Centers for Disease Control and Prevention (CDC).
Clark Health Communications
Kirsty Somerscales
Clark Health Communications has appointed Kirsty Somerscales as its new senior account director. Somerscales joined the agency in February 2021 and has successfully mentored the team, providing leadership on client accounts in change management, vaccines and telehealth. As part of her new role, she will provide input into the agency’s strategic direction and support the internal people work-stream.
Clark Health Communications
Emily Coppen
Clark Health Communications has appointed Emily Coppen as an account director. She will lead key accounts in vaccines, women’s health, internal communications and will drive CHC’s marketing team. Coppen brings over six years’ experience in delivering healthcare communications and patient advocacy programmes in the UK. She previously worked at HAVAS Just:: working on a global level overseeing agency culture development projects.
Clark Health Communications
Jessica Lowrie
Clark Health Communications has appointed Jessica Lowrie as an account director. Lowrie joins with over eight years of experience in the healthcare industry and will focus on key accounts in oncology, internal communications and patient advocacy. She will also lead the omnichannel work stream for CHC. Previously, she managed the global marketing communications for a leading clinical diagnostic laboratory in Canada.
The Creative Engagement Group
Tom Griffiths
The Creative Engagement Group has appointed Tom Griffiths as its new strategy and planning director. Griffiths joins from Saatchi & Saatchi Wellness where he was an integrated strategy director. Previously, he served as digital strategy director in the greyhealth group, part of WPP Health & Wellness. Tom has driven creative and brand strategy for Bayer, Pfizer, Sanofi, Galderma and GSK.
Kanga Health
Paul Allen
Kanga Health has appointed Paul Allen as its new managing director. In his new role, he will oversee the daily running of the business. Allen has over 20 years’ experience of delivering digital work across industries, having joined Kanga Health in 2013. He has previously served as the agency’s programme director and subsequently as chief operations officer over his nine-year tenure.
Society for Health Communication
Michael Grela
The Society for Health Communication has appointed Michael Grela as its president. Grela serves at Evoke KYNE as its executive vice president, head of reputation and social impact. As president, Grela will oversee the Society’s newly expanded Steering Committee and will focus on its member engagement, diversity, equity and inclusion. Grela most recently served as the Steering Committee’s vice president.
Twist Health
Sean McGrath
Twist Health has appointed Sean McGrath as a non-executive director. With a career spanning 30 years in senior roles, McGrath has also built his own international medical communications practice, Succinct. He previously served at My Name’5 Doddie (MND) Foundation as a medical strategy lead. In his new position, he will support the service delivery to clients and the wider pharmaceutical industry.